 Orgenesis Inc NASDAQ:ORGS FRA:45O is poised to carry out the first-in-human trial of its Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome ARDS caused by the coronavirus COVID-19 after receiving the go-ahead from the US Food and Drug Administration FDA. The cell and gene therapies CGTs focused biotech described being granted the Investigational Device Exemption IDE approval for the pilot trial as a significant milestone for the company. 